A Study of ALT-836 in Combination With Gemcitabine for Locally Advanced or Metastatic Solid Tumors

Inclusion criteria

DISEASE CHARACTERISTICS: * Histologically or cytologically confirmed * Locally advanced or metastatic non-hematologic malignancies * Measureable * Refractory to standard therapies or single agent gemcitabine is indicated as a standard treatment option PRIOR/CONCURRENT THERAPY: * No concurrent radiotherapy, chemotherapy, immunotherapy or other investigational agents * Must have recovered from side effects of prior therapies PATIENT CHARACTERISTICS: Life expectancy * \> 12 weeks Performance Status * ECOG 0 or 1 Bone Marrow Reserve * Absolute Neutrophil count (AGC/ANC) ≥ 1,500/uL * Platelets ≥ 100,000/uL * Hemoglobin \> 9 g/dL Renal Function * Calculated Glomerular filtration rate (GFR) \> 59mL/min/1.73M\^2 Hepatic Function * Total bilirubin ≤ 1.5 X ULN * AST, ALT, and ALP ≤ 3 X ULN or ≤ 5.0 x ULN, if liver metastasis exists * PT INR ≤ 1.5 X ULN Cardiovascular * No history of clinically significant vascular disease * No New York Heart Association (NYHA) Class \> II heart failure Hematologic * No history of bleeding disorders * No evidence of bleeding diathesis or coagulopathy * No presence of clinically significant hemoptysis or hematuria, presence of serious non-healing wound or ulceration, or signs of other bleeding * No evidence of a tumor invasion of any major blood vessel * No trauma with increased risk of life-threatening bleeding or history of severe head trauma or intracranial surgery within two months of study entry Surgery/Procedures * No major surgery or open biopsy within 28 days before drug infusion or evidence of active bleeding postoperatively * No plan for any major surgery during treatment period * No presence or requirement of an epidural catheter or lumbar puncture within 48 hours prior to each dose of study treatment * No anticipation of receiving an epidural catheter or a lumbar puncture within 48 hours after each dose of study treatment Excluded Medications or Treatment Regimens * Unfractionated heparin of \> 15,000 units/day within 8 hours prior to each dose of study treatment * Low-molecular weight heparin at a higher dose than recommended for prophylactic used or required within 20 hours prior to each dose of study treatment * Warfarin used or required within 48 hours prior to each dose of study treatment and the prothrombin time (INR) exceeded the upper limit of normal range * Direct thrombin inhibitors or Xa inhibitors * Acetylsalicylic acid used or required within 72 hours prior to each dose of study treatment * Clopidogrel bisulfate used or required within 48 hours prior to each dose of study treatment * Anticipated requirement for anti-platelet or anti-coagulant agents excluding non-aspirin NSAID within 48 hours following study treatment infusion Other * No active systemic infection requiring parenteral antibiotic therapy * No history of or presence of a CNS disease * No history of allergic reactions to compounds of similar chemical or biologic composition * Not HIV positive * No women who are pregnant or nursing * A negative serum pregnancy test if female * Patients, both females and males, with reproductive potential must agree to use effective contraceptive measures for the duration of the study * No history of significant renal, endocrinologic, metabolic, immunologic or hepatic disease * No evidence of psychiatric illness/social situations * Other illness that in the opinion of the investigator would exclude the patient from participating * Must provide informed consent and HIPAA authorization and comply with protocol-specified procedures and follow-up evaluations